argenx SE

argenx SE is a commercial-stage, global, fully-integrated biopharmaceutical company headquartered in Amsterdam, Netherlands, specializing in the development of differentiated antibody-based therapies for severe autoimmune diseases. The company leverages its Immunology Innovation Program (IIP), a discovery engine that fosters collaborations with academic and scientific partners to translate immunology breakthroughs into novel medicines. Key technologies include the SIMPLE ANTIBODY™ platform, derived from llama immune systems for accessing complex targets, and Fc engineering tools like NHANCE™, ABDEG™, and POTELLIGENT® to enhance antibody properties such as half-life and potency. argenx SE has commercialized VYVGART, the first approved FcRn blocker available in intravenous and subcutaneous forms, primarily for generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP). Its pipeline features empasiprubart, a C2 inhibitor in Phase 3 for multiple autoimmune indications, ARGX-119, a MuSK agonist for neuromuscular disorders, and several preclinical candidates targeting FcRn, IgA, IL-6, and other immune pathways. With subsidiaries across Europe, North America, Asia, and Australia, argenx SE plays a pivotal role in advancing immunology-focused biopharmaceutical innovation, aiming to address unmet needs in immunology through co-creation and antibody engineering expertise.

¿Quieres entender cómo evaluamos la seguridad de los dividendos? Lee nuestra metodología completa